{"filing":{"accession_number":"0001213900-26-071076","cik":"0001871321","ticker":"DRTSW","company_name":"Alpha Tau Medical Ltd.","form":"6-K","filing_date":"2026-06-23","report_date":null,"primary_document":"ea0295467-6k_alpha.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1871321/000121390026071076/ea0295467-6k_alpha.htm"},"events":[{"id":13130,"run_id":11653,"accession_number":"0001213900-26-071076","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces the first successful clinical treatment of a glioblastoma patient outside the United States using Alpha Tau's proprietary Alpha DaRT technology, performed at Hadassah University Medical Center in Israel. The disclosure represents a material operational and clinical milestone for the company's development program—the first international application of the brain-specific delivery system and a proof-of-concept for the technology in a high-unmet-need indication. While not a discrete event type (not M\u0026A, not an earnings release, not an executive change), this clinical achievement is material to investors assessing the company's progress toward commercialization and regulatory approval of its core therapeutic platform.","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-06-23","form":"6-K","submitted_at":null,"items":[{"id":10184,"accession_number":"0001213900-26-071076","item_number":"EX-99.1","item_title":"ea029546701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the first successful clinical treatment of a glioblastoma patient outside the United States using Alpha Tau's proprietary Alpha DaRT technology, performed at Hadassah University Medical Center in Israel. The disclosure represents a material operational and clinical milestone for the company's development program—the first international application of the brain-specific delivery system and a proof-of-concept for the technology in a high-unmet-need indication. While not a discrete event type (not M\u0026A, not an earnings release, not an executive change), this clinical achievement is material to investors assessing the company's progress toward commercialization and regulatory approval of its core therapeutic platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:03:38.740088+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10184,"accession_number":"0001213900-26-071076","item_number":"EX-99.1","item_title":"ea029546701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces the first successful clinical treatment of a glioblastoma patient outside the United States using Alpha Tau's proprietary Alpha DaRT technology, performed at Hadassah University Medical Center in Israel. The disclosure represents a material operational and clinical milestone for the company's development program—the first international application of the brain-specific delivery system and a proof-of-concept for the technology in a high-unmet-need indication. While not a discrete event type (not M\u0026A, not an earnings release, not an executive change), this clinical achievement is material to investors assessing the company's progress toward commercialization and regulatory approval of its core therapeutic platform.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:03:38.740088+00:00","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-06-23"}]}